Skip to content
Optionomics Free · No account needed

Earnings analysis · 10-Q

OABI earnings analysis

Filed May 7, 2026 · Our reading of the company's report

The latest report

OmniAb, Inc. reported strong Q1 2026 results with revenues of $14.4 million, a significant increase from $4.2 million in the prior year, and an EPS loss of -$0.06, outperforming expectations. The company raised its…

Read full summary

OmniAb, Inc. reported strong Q1 2026 results with revenues of $14.4 million, a significant increase from $4.2 million in the prior year, and an EPS loss of -$0.06, outperforming expectations. The company raised its full-year revenue guidance to between $28 million and $33 million, reflecting robust developments in its partner programs.

Read the original on SEC.gov

Gross and operating margin

How much of each revenue dollar the business keeps.

100% Gross margin Operating margin May 2023 Mar 2026

One point per quarterly or annual filing. Both margins are shares of that report's revenue.

How we read each report

Our analysis across the last few reports.

Read as bullish Read as bearish Nov 2021 May 2026

Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.

Reported figures

Earnings per share
$-0.06

What stood out

  • Revenue Up 247% YoY

    Q1 2026 revenue reached $14.4 million, up from $4.2 million in Q1 2025.

  • EPS Loss Narrowed

    Reported EPS loss was -$0.06, compared to -$0.17 in Q1 2025.

  • Significant Milestone Revenue Growth

    License and milestone revenue surged to $12.0 million from $2.0 million, a 495% increase.

  • Improvement in Operating Cash Flow

    Operating cash flow improved to -$4.9 million from -$15.9 million in Q1 2025.

  • Cost Management Success

    Research and development expenses decreased by 24% year-over-year to $9.64 million.

  • Revised Revenue Guidance

    Full-year revenue guidance raised to $28 million to $33 million, up from $25 million to $30 million.

What to watch

  • High Cash Burn Rate

    Cash used in operating activities was $4.9 million, albeit improved from $15.9 million in the prior year.

  • Regulatory Risks

    The company is heavily reliant on partners for commercialization and regulatory approvals of drugs.

  • Market Acceptance Uncertainties

    Future revenues hinge on partner success in drug development and market acceptance of therapies.

Management's outlook

Guidance raised from previous estimates of $25 million to $30 million.

Earlier filings 4

10-K · March 4, 2026

OmniAb positions itself as a multi-species, biologically driven antibody discovery platform that licenses technology to partners and collects access fees, services, milestones and royalties. The company reported a large…

10-K · March 18, 2025

OmniAb positions itself as a platform company that licenses a four‑species transgenic animal and high‑throughput screening stack (OmniAb, OmniDeep, xPloration/GEM) to pharma/biotech partners; as of December 31, 2024 it…

10-K · March 25, 2024

OmniAb positions itself as a partner‑centric antibody discovery platform with a differentiated four‑species technology suite (OmniRat, OmniMouse, OmniChicken, OmniTaur) and new in‑silico/AI tools (OmniDeep launched May…

10-Q · August 10, 2023

OmniAb reported Q2 revenue of $6,946,000 (three months ended June 30, 2023) vs $7,199,000 in the year-ago quarter, with net loss of $14,728,000 (loss per share $0.15). License & milestone revenue rose materially while…

This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.